Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共4页
• 作者

  van de Loosdrecht Arjan A.; Chitu Dana A.; Cremers Eline M. P.; Westers Theresia M.; Alhan Canan; Visser-Wisselaar Heleen; Verbrugge Annelies; Muus Petra; de Greef Inge; Wijermans Pierre W.; Jansen Joop H.; Klein Saskia K.; Vellenga Edo; Legdeur Marie-Cecile; Deenik Wendy; Jongen-Lavrencic Mojca; van Marwijk-Kooy Rien; Tanis Bea; Wegman Jurgen; van Maanen Tanja; Ossenkoppele Gert;

  展开▼
• 作者单位

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词